- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02057445
3rd Party LMP1/2-Specific Cytotoxic T Lymphocytes for EBV-Associated Lymphoma
A Multicenter Pilot Study of Third Party LMP1/2-Specific Cytotoxic T Lymphocytes for Treatment of Patients With Refractory /Relapsed EBV-Associated Lymphoma A Childhood, Adolescent and Young Adult Lymphoma Cell Therapy Consortium (LCTC) Multicenter Clinical Trial
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
District of Columbia
-
Washington, District of Columbia, United States
- Children's National Medical Center
-
-
New York
-
Valhalla, New York, United States, 10595
- New York Medical College
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patient must be at least 1 year of age.
Patient or the patient's legally authorized guardian must be fully informed about their illness and the investigational nature of the study protocol (including foreseeable risks and possible side effects), and must sign an informed consent in accordance with the institutional policies approved by the U.S. Department of Health and Human Services.
Patients should have been off other investigational therapy for one month prior to entry in this study.
Patient must have adequate organ function as below:
Adequate renal function defined as:
- Serum creatinine <2.0 x normal, or
- Creatinine clearance or radioisotope GFR > 40 ml/min/m2 or >60 ml/min/1.73 m2 or an equivalent GFR as determined by the institutional normal range
Adequate liver function defined as:
- Total bilirubin <2.0 x normal; and
- SGOT (AST) or SGPT (ALT) <5.0 x normal
Adequate pulmonary function defined as:
- Pulse oximetry >94% in room air. Lansky (< 16yr) or Karnofsky (> 16 yrs) performance status ≥ 50% Life expenctancy ≥ 6 weeks. Women of child bearing age require a negative urine pregnancy test. Clinical status at enrollment to allow tapering of steroids to less than 0.5mg/kg/day prednisone at time of treatment.
4.5 Disease Status (Eligibility) 4.5.1 Any patient, with one or more of the following EBV-positive type II latency or associated disorders, regardless of the histological subtype: Hodgkin lymphoma Non-Hodgkin lymphoma Lymphoproliferative disorder Severe chronic active EBV infection syndrome (SCAEBV), defined as high EBV viral load in plasma or PBMC (> 4000 genomes per μg PBMC DNA) and/or biopsy tissue positive for EBV
The disease needs to be in one of the following stages:
At diagnosis who would be unable to receive conventional chemotherapy or in first relapse AND the patient is not a candidate for HSCT Partial response after conventional therapy. Refractory to conventional therapy for his/her condition. In second or subsequent relapse. Residual disease after autologous, syngeneic or allogeneic HSCT.
All patients entered into the study ideally will have tumor tissue from the original diagnostic specimen and/or relapse reviewed centrally for confirmation of EBV positive disease. If no specimen is available, local pathology report documenting EBV positivity is acceptable. Appropriate immunophenotyping to confirm the diagnosis will be performed. In addition, in situ hybridization for EBV (LMP1, and/or EBER positivity) will be performed. All central morphologic analysis and immunohistochemical/insitu hybridization staining will be performed in the laboratory of Sherrie Perkins and Rodney Miles at the University of Utah.
Donor Eligibility for LMP-CTL Third Party Banking (Aim 2.1.2)
- Donor must be HIV negative.
- Donors must have adequate hematopoietic function defined as absolute neutrophil count > 1000/mm3, hemoglobin > 10 g/dl, and platelet count >50,000/mm3 and be EBV IgG seropositive.
- Donors will have peripheral blood collected for LMP specific CTL production. A minimum of 60 cc of peripheral blood x 2 for a total maximum amount of blood of 120cc, will be collected from the donor (subjects must be at least 12 kg or 24 pounds). (See Appendix B) For donors <18 years a maximum of 3cc/kg blood will be taken in an 8 week period.
- For donors that are to undergo stem cell collection, the peripheral blood for LMP specific CTL production will be collected prior to the stem cell collection and without a specific day specification.
- Donor eligibility must meet criteria as per 21 CFR 1271.
Exclusion Criteria:
Currently receiving any investigational agents or have received any tumor vaccines within previous 4 weeks.
Active acute grade III-IV graft-versus-host disease. Severe refractory intercurrent infection other than EBV. Received alemtuzumab or other anti-Tcell antibody within 28 days. HIV seropositivity. Pregnancy (due to unknown effects of this therapy on a fetus) or lactation. Patients with PTLD post solid organ transplantation eligible for the COG PTLD LMP/CTL protocol.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Recipient
EBV+ patients will receive 3rd party LMP-CTLs for treatment of EBV infection and/or disease
|
Eligible patients with a matched cell line will be infused with 3rd party CTLs and monitored for adverse events and response.
Patients who show a response and tolerate the infusion well may receive up to 5 infusions total 4-6 weeks apart.
|
Other: Donor
Healthy donors who are EBV+ will be asked to donate 60-120 ml of peripheral blood for development of cell lines to be stored for cell line bank.
|
Donors who are EBV+ and meet the eligibility criteria will be consented to provide 60-120 ml peripheral blood once for future use for this and other clinical trials using 3rd party CTLs.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To determine the safety of giving 3rd party EBV-CTLs
Time Frame: 1 year
|
Patients will be monitored for any unexpected adverse events related to investigational product.
|
1 year
|
To develop a third party bank of LMP-specific CTL
Time Frame: on going
|
EBV positive donors will be asked to provide an extra sample of peripheral blood to build a donor bank of EBV-CTLs for this protocol and future use.
|
on going
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To measure the response rate
Time Frame: 1 year
|
patients will be followed a year following administration of cells for disease response.
|
1 year
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Catherine Bollard, MD, Children's National Research Institute
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NYMC-561
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-Hodgkins Lymphoma
-
Baylor College of MedicineCenter for Cell and Gene Therapy, Baylor College of MedicineRecruitingHodgkins Lymphoma | Non Hodgkins LymphomaUnited States
-
Spectrum Pharmaceuticals, IncCompletedNon-Hodgkins Lymphoma | Tumors | Hodgkins DiseaseUnited States, Canada
-
Children's Hospital Los AngelesCompletedHodgkins Lymphoma | Non-hodgkins LymphomaUnited States
-
Weill Medical College of Cornell UniversityCompletedHodgkins Disease | Lymphoma, Non-HodgkinsUnited States
-
SCRI Development Innovations, LLCBiogenCompleted
-
University of Wisconsin, MadisonNational Cancer Institute (NCI); Pfizer; Millennium Pharmaceuticals, Inc.CompletedNon-Hodgkins LymphomaUnited States
-
Maisonneuve-Rosemont HospitalBayerUnknownNon-Hodgkins LymphomaCanada
-
National Cancer Institute (NCI)TerminatedLeukemia | Multiple Myeloma | MDS | Non-Hodgkins Lymphoma | Hodgkins LymphomaUnited States
-
University of NebraskaSchering-PloughCompletedNon-Hodgkins LymphomaUnited States
-
Royal Marsden NHS Foundation TrustCompleted
Clinical Trials on EBV CTL's
-
Baylor College of MedicineThe Methodist Hospital Research Institute; Center for Cell and Gene Therapy...CompletedT-Lymphocytes in Treating Patients With Epstein-Barr Virus-Positive Nasopharyngeal Cancer, NPC (NPC)Head and Neck CancerUnited States
-
Baylor College of MedicineThe Methodist Hospital Research Institute; Center for Cell and Gene Therapy...Active, not recruitingHodgkin's Lymphoma | Non-Hodgkin's LymphomaUnited States
-
Heidelberg UniversityCompleted
-
St. Justine's HospitalCanadian Blood ServicesUnknownLymphoproliferative DisordersCanada
-
Baylor College of MedicineThe Methodist Hospital Research Institute; Center for Cell and Gene Therapy...CompletedHER2 Positive MalignanciesUnited States
-
Baylor College of MedicineCenter for Cell and Gene Therapy, Baylor College of MedicineActive, not recruiting
-
Sun Yat-sen UniversityActive, not recruitingNasopharyngeal CarcinomaChina
-
Taichung Veterans General HospitalUnknownNasopharyngeal CarcinomaTaiwan
-
Chinese PLA General HospitalRecruitingEBV Infection After Allogenic HSCTChina
-
Hebei Yanda Ludaopei HospitalChina Immunotech (Beijing) Biotechnology Co., Ltd.CompletedEBV Emia and EBV Positive PTLD After Allogenic HSCTChina